Clinical Trials News

Latest clinical-trials news and updates for US-listed public companies.

📣 Get clinical-trials alerts and analysis

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying it...

What is the estimated market size for the TRACTr therapy and its potential long‑term impact on Janux's valuation? What are the projected patient enrollment rates and trial size, and could any challenges in enrollment delay timelines? How will this clinical milestone be incorporated into Janux's revised earnings forecasts and revenue projections?
Symbol: JANX
19 days ago
Read more businesswire

Butterfly Network Advances AI-Powered Aortic Valve and Aorta Screening with New Research and Training Tools

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today an...

How does this AI‑driven capability compare to competitor offerings in terms of accuracy, workflow integration, and cost‑effectiveness? Will the new tools lead to increased device utilization and unit sales, thereby expanding the addressable market and market share? What potential reimbursement challenges exist for AI‑assisted aortic stenosis screening, and how might they impact profitability?
Symbol: BFLY
19 days ago
Read more businesswire

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be p...

What are the anticipated pricing and reimbursement scenarios for IBTROZI™ if it receives approval? What are the key risk factors (e.g., safety concerns, enrollment delays) that could affect investor confidence? How will the results affect the valuation of NUVB relative to its peers (e.g., Incyte, Merck, Bristol‑Myers Squibb) in the oncology space?
Symbol: NUVB
19 days ago
Read more businesswire

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced plans to announce topline data from its phase 3 registrational clinical trial of ZYN002 in ...

How might the Q2 2025 WAKIX revenue growth influence the company's 2025 revenue guidance revisions? Will the company need to raise additional capital to fund commercialization of ZYN002, and what impact could that have on dilution? What is the competitive landscape for Fragile X treatments and how might ZYN002’s results position HRMY against peers?
Symbol: HRMY
19 days ago
Read more businesswire

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal announces clinical trial initiation plans for tecarfarin in patients with end-stage kidney disease (ESKD) who are transitioning to dialysis

How does the expected cost of the trial compare to previous clinical programs run by Cadrenal? Will the company’s cash runway be sufficient to fund the trial without diluting existing shareholders? What is the potential competitive landscape if Tecarfarin reaches the market—who are the main rivals?
Symbol: CVKD
20 days ago
Read more businesswire

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ra...

How might the market’s perception of Vertex’s R&D capabilities change after this disclosure? What are the implications for Vertex's overall pipeline valuation given this setback? Could the results lead to a strategic partnership, licensing deal, or asset divestiture for Vertex?
Symbol: VRTX
20 days ago
Read more businesswire

Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-gener...

What potential regulatory pathway (e.g., FDA accelerated approval, cardiovascular outcome trial) does Marea anticipate for MAR001 if Phase 2b data are positive? How might the results of TYDAL‑TIMI 78 position MAR001 for advancement into a Phase 3 program, and what timelines are expected for that transition? What safety signals have emerged in Phase 1 or early Phase 2 data, and how might they influence investor sentiment?
Symbol: MREA
20 days ago
Read more businesswire

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogen...

What are the company’s projected costs for advancing the DOSED trial through Phase 2/3, and how will this affect runway and potential dilution? Are there any disclosed adverse events or safety signals from this first patient that could raise concerns among investors? What is the estimated market size for subacute and chronic spinal cord injury treatments, and what share can Lineage realistically capture if trials are successful?
Symbol: LCTX
20 days ago
Read more businesswire